Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Operations: 2015-2025

Historic Cash from Operations for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -$15.6 million.

  • Cartesian Therapeutics' Cash from Operations fell 213.94% to -$15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$63.2 million, marking a year-over-year decrease of 58.24%. This contributed to the annual value of -$23.7 million for FY2024, which is 53.73% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Cash from Operations of -$15.6 million as of Q3 2025, which was up 10.96% from -$17.5 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Cash from Operations ranged from a high of $13.7 million in Q3 2024 and a low of -$31.5 million during Q4 2021.
  • Its 3-year average for Cash from Operations is -$11.9 million, with a median of -$14.4 million in 2024.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 333.93% in 2021, then soared by 248.57% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Cash from Operations (Quarterly) stood at -$31.5 million in 2021, then skyrocketed by 62.34% to -$11.8 million in 2022, then crashed by 96.52% to -$23.3 million in 2023, then skyrocketed by 69.93% to -$7.0 million in 2024, then slumped by 213.94% to -$15.6 million in 2025.
  • Its Cash from Operations was -$15.6 million in Q3 2025, compared to -$17.5 million in Q2 2025 and -$23.1 million in Q1 2025.